10x Genomics Announces Preliminary Select Third Quarter 2024 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Citi Reiterates Buy Rating on 10X Genomics (TXG)
October 10, 2024 5:51 AM EDTCiti analyst Patrick Donnelly reiterated a Buy rating and $35.00 price target on 10X Genomics (NASDAQ: TXG).
The analyst comments "TXG announced preliminary 3Q24 results, falling well short of expectations with single cell and Spatial both missing. Total 3Q revenue of $151.7mn was... More
BofA Securities Reiterates Neutral Rating on 10X Genomics (TXG)
October 10, 2024 5:32 AM EDTBofA Securities analyst Derik de Bruin reiterated a Neutral rating and $25.00 price target on 10X Genomics (NASDAQ: TXG).
The analyst comments "After market close, TXG negatively preannounced 3Q results. Total sales of $151.6mn missed consensus ($162.3mn) by a wide margin, and... More
